A5035508230- Prostate Cancer Treatment and Research
- Cancer, Hypoxia, and Metabolism
- Estrogen and related hormone effects
- Ubiquitin and proteasome pathways
- Hormonal and reproductive studies
- Protein Degradation and Inhibitors
Fred Hutch Cancer Center
2023
Prostate cancer (PC) is driven by androgen receptor (AR) activity, a master regulator of prostate development and homeostasis. Frontline therapies for metastatic PC deprive the AR activating ligands testosterone (T) dihydrotestosterone (DHT) limiting their biosynthesis or blocking binding. Notably, signaling dichotomous, inducing growth at lower activity levels, while suppressing higher levels. Recent clinical studies have exploited this effect administration supraphysiological...
The androgen receptor (AR) pathway regulates key cell survival programs in prostate epithelium. AR represents a near-universal driver and therapeutic vulnerability metastatic cancer, targeting has remarkable index. Though most approaches directed toward focus on inhibiting signaling, laboratory now clinical data have shown that high dose, supraphysiological treatment (SPA) results growth repression improved outcomes subsets of patients with cancer. A better understanding the mechanisms...
<div>Abstract<p>The androgen receptor (AR) pathway regulates key cell survival programs in prostate epithelium. The AR represents a near-universal driver and therapeutic vulnerability metastatic cancer, targeting has remarkable index. Though most approaches directed toward focus on inhibiting signaling, laboratory now clinical data have shown that high dose, supraphysiological treatment (SPA) results growth repression improved outcomes subsets of cancer patients. A better...
<p>Supplemental Figures 1-4</p>
<p>Supplemental Figures 1-4</p>
<div>Abstract<p>The androgen receptor (AR) pathway regulates key cell survival programs in prostate epithelium. The AR represents a near-universal driver and therapeutic vulnerability metastatic cancer, targeting has remarkable index. Though most approaches directed toward focus on inhibiting signaling, laboratory now clinical data have shown that high dose, supraphysiological treatment (SPA) results growth repression improved outcomes subsets of patients with cancer. A better...
<div>Abstract<p>The androgen receptor (AR) pathway regulates key cell survival programs in prostate epithelium. The AR represents a near-universal driver and therapeutic vulnerability metastatic cancer, targeting has remarkable index. Though most approaches directed toward focus on inhibiting signaling, laboratory now clinical data have shown that high dose, supraphysiological treatment (SPA) results growth repression improved outcomes subsets of cancer patients. A better...
<p>Supplemental Figures 1-4</p>
<p>Supplemental Figures 1-4</p>